Jump to main content
Jump to site search

Issue 53, 2019
Previous Article Next Article

A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

Author affiliations

Abstract

Despite their attractive properties, internal targeted alpha therapies using 223/224Ra are limited to bone-seeking applications. As there is no suitable chelator available, the search for new carriers to stably bind Ra2+ and to connect it to biological target molecules is necessary. Polyoxopalladates represent a class of compounds where Ra2+ can be easily introduced into the Pd-POM core during a facile one-pot preparation. Due to the formation of a protein corona, the connection to other targeting (bio)macromolecules is possible.

Graphical abstract: A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

Back to tab navigation

Supplementary files

Publication details

The article was received on 03 Apr 2019, accepted on 04 Jun 2019 and first published on 04 Jun 2019


Article type: Communication
DOI: 10.1039/C9CC02587A
Chem. Commun., 2019,55, 7631-7634

  •   Request permissions

    A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

    M. Gott, P. Yang, U. Kortz, H. Stephan, H. Pietzsch and C. Mamat, Chem. Commun., 2019, 55, 7631
    DOI: 10.1039/C9CC02587A

Search articles by author

Spotlight

Advertisements